Published • loading... • Updated
ABL TEXTELL DIAGNOSTICS RELATING ITS OBJECTIVE TO FURTHER BUSINESS 2026 TO A FOURCHETTE FROM €13.5 M TO €14.0 M
Summary by Business Wire
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6), a company specializing in molecular diagnostic solutions, health software and services associated with clinical research and biopharmaceutical development, raises its turnover target for the year ended 31 December 2026. Based on the commercial, operational and accounting information available at the date of this press release, the Soci
·Crystal River, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
